Scientists discover new hope for the treatment and prevention of osteoporosis.

A new hope is emerging in understanding how bone health and osteoporosis work, which may drive more effective treatments through new research. The study on the membrane receptor GPR133/ADGRD1 revealed a groundbreaking discovery about how our bones grow and strengthen, pointing to a new therapeutic target to prevent and treat diseases such as osteoporosis.

What is GPR133/ADGRD1 and why is it important?

GPR133/ADGRD1 is a special type of receptor known as an adhesion GPCR, located on the surface of bone cells, mainly osteoblasts — the cells responsible for producing new bone tissue. Genetic studies have shown that variations in the gene encoding this receptor are linked to both bone mineral density and human height — meaning its function directly influences bone strength and, to some extent, physical characteristics such as stature.

How does GPR133 strengthen bones?

This receptor responds to two types of stimuli:

• Chemical signals from a protein called PTK7, which binds to the receptor and activates it.

• Mechanical stimuli, such as impact or exercise, which also activate the receptor.

When activated, GPR133 triggers processes inside cells through messenger molecules such as cAMP, which activate the β-catenin signaling pathway — crucial for turning stem cells into mature osteoblasts, responsible for building more bone matrix and promoting bone mineralization.

What happens if this receptor doesn’t work?

Experiments with mice lacking Gpr133 showed thinner, weaker bones with less new tissue, even when the body tried to compensate by forming more osteoclasts (cells that break down bone). The impact was observed in major limbs and the spine, indicating an increased risk of fractures — typical features of osteoporosis.

In addition, increased osteoclast activity in these animals led to excessive bone resorption, showing that the balance between bone formation and destruction depends on the proper functioning of GPR133.

Drug testing: a revolutionary potential

Scientists have developed a chemical compound called AP503 capable of precisely activating GPR133. In animal models, administration of this compound produced remarkable effects:

• It increased bone density and strength, even reversing conditions similar to osteoporosis caused by artificial menopause.

• The treatment worked synergistically with physical exercise: mice that received the drug and exercised regained bone tissue far more effectively than with currently available treatments.

• Another agonist, called GL64, also showed a protective effect on bone by reducing the activity of bone-destroying cells and acting through the cAMP-PKA-NFATC1 pathway, an essential branch in maintaining bone balance.

Why is this a breakthrough for medicine?

Currently, medications used against osteoporosis generally act on only one side of the problem: they reduce bone loss but have limited ability to stimulate new bone formation and may cause serious long-term side effects. GPR133 emerges as a dual solution capable of restoring the natural balance between bone formation and resorption while also responding to mechanical exercise stimuli — combining health and lifestyle.

Future implications and social relevance

• This advancement directly addresses a growing public health demand, as osteoporosis is becoming increasingly common in aging populations.

• New drugs based on this receptor may be more effective, with lower risk of side effects and greater potential for functional recovery.

• This therapeutic target may also benefit those with a genetic predisposition to bone loss, promoting personalized treatments.

This type of research exemplifies how understanding molecular mechanisms can open the door to innovative approaches, combining genetics, pharmacology, cell biology, and physical stimulation in the quest for stronger, healthier bones.

Sources for this article: